Investor Intelligence

Chasing growth stocks can make you rich. It can also blow up your portfolio. In this episode, Finimize Analyst Stéphane Renevier joins the pod to share the CANSLIM method - a system for finding high-growth stocks and knowing when to actually pull the trigger.  It’s all about discipline, timing, and spotting key signals before a stock breaks out.  Plus: he’s got a few names on his watchlist right now. Try Finimize Pro [https://finimize.com/join]

Intel, nuclear, and utilities aren’t exactly the flashiest parts of the market. But they’ve quietly been at the centre of some of the biggest investment themes of the past year. In today’s episode, Finimize Analyst Reda Farran joins the pod to see what’s changed since he first made the case.  Some calls have aged well. Others? Not so much.  We revisit the original theses, update the outlook, and figure out where the opportunity still is - and where it might be time to take profits. Try Finimize Pro [https://finimize.com/join]

Starbucks feels like the kind of stock you should want to own.  It’s everywhere, it’s addictive, and it’s managed to charge more and more without losing the crowd. But when Finimize Analyst Theodora Lee Joseph took a closer look, the story wasn’t quite so frothy. In today’s episode, she explains why the coffee giant’s growth has slowed, costs have crept up, and yet… the stock still trades like a rebound’s already here.  It’s not a short call, and it’s definitely not broken.  But it might not be the no-brainer compounder everyone assumes. Try Finimize Pro [https://finimize.com/join]

Duolingo’s stock has soared.  But is it still a smart bet, or just a cute owl in a bubble? In today’s episode, Finimize Analyst Stéphane Renevier joins the show. He's  built a fast, repeatable way to analyse any high-growth company - using AI, some classic fundamentals, and about three hours of your time.  No fluff, no 80-tab spreadsheets. Just the stuff that matters: how the company makes money, what the numbers say, and where the real risks and rewards might lie. He walks us through the seven-step playbook using Duolingo as the example - but trust us, you’ll want to steal this framework for your next stock pick too. Try Finimize Pro [https://finimize.com/join]

Ozempic’s still the hottest drug on the planet.  But Novo Nordisk’s stock? Not so much. It’s down nearly 50% from its peak, and investors aren’t sure whether to double down or walk away.  In today’s episode, Finimize Analyst Russell Burns, whose latest research unpack's  what’s really going on with the stock, joins the pod. Is this just a healthy correction? Or the kind of long-term opportunity you only get when everyone else is panicking? Try Finimize Pro [https://finimize.com/join]